Carlyle Group Files 13D/A for QuidelOrtho Corp

Ticker: CGABL · Form: SC 13D/A · Filed: Jul 30, 2024 · CIK: 1527166

Carlyle Group Inc. SC 13D/A Filing Summary
FieldDetail
CompanyCarlyle Group Inc. (CGABL)
Form TypeSC 13D/A
Filed DateJul 30, 2024
Risk Levelmedium
Pages8
Reading Time10 min
Key Dollar Amounts$0.001, $37.77, $39.80, $38.9681, $38.04
Sentimentneutral

Sentiment: neutral

Topics: ownership-change, sec-filing, schedule-13d

Related Tickers: QDEL

TL;DR

Carlyle Group updated its 13D filing for QuidelOrtho (QDEL) - ownership details changed.

AI Summary

Carlyle Group Inc. filed an amendment to its Schedule 13D on July 30, 2024, related to its beneficial ownership of QuidelOrtho Corp. The filing indicates a change in the reporting person's holdings, though specific new dollar amounts or percentages are not detailed in this excerpt. The amendment pertains to QuidelOrtho Corp, a company involved in in vitro and in vivo diagnostic substances.

Why It Matters

This filing signals a potential shift in significant ownership stakes for QuidelOrtho Corp, which could influence its stock price and strategic direction.

Risk Assessment

Risk Level: medium — Schedule 13D filings often precede significant corporate actions or shifts in control, which can introduce volatility.

Key Players & Entities

  • Carlyle Group Inc. (company) — Filer of the Schedule 13D/A
  • QuidelOrtho Corp (company) — Subject company of the filing
  • 20240730 (date) — Filing date

FAQ

What specific changes in beneficial ownership are reported by Carlyle Group Inc. in this 13D/A filing?

The provided excerpt states that the filing is an amendment to Schedule 13D and indicates a change in the reporting person's holdings, but does not specify the exact nature or extent of these changes.

What is the Central Index Key (CIK) for QuidelOrtho Corp?

The CIK for QuidelOrtho Corp is 0001906324.

What is the business address of QuidelOrtho Corp?

The business address for QuidelOrtho Corp is 9975 Summers Ridge Road, San Diego, CA 92121.

What is the CIK for Carlyle Group Inc.?

The CIK for Carlyle Group Inc. is 0001527166.

What is the SIC code for QuidelOrtho Corp?

The Standard Industrial Classification (SIC) code for QuidelOrtho Corp is 2835, which corresponds to 'IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES'.

Filing Stats: 2,462 words · 10 min read · ~8 pages · Grade level 8 · Accepted 2024-07-30 16:30:07

Key Financial Figures

  • $0.001 — relating to the common stock, par value $0.001 per share (the “Common Stock&rdqu
  • $37.77 — ice Per Share July 24, 2024 214,732 $37.77 to $39.80 $38.9681 July 25, 2024 40
  • $39.80 — are July 24, 2024 214,732 $37.77 to $39.80 $38.9681 July 25, 2024 406,809 $38
  • $38.9681 — ly 24, 2024 214,732 $37.77 to $39.80 $38.9681 July 25, 2024 406,809 $38.04 to $39
  • $38.04 — .80 $38.9681 July 25, 2024 406,809 $38.04 to $39.4432 $38.585 July 26, 2024 1
  • $39.4432 — 681 July 25, 2024 406,809 $38.04 to $39.4432 $38.585 July 26, 2024 103,926 $38.
  • $38.585 — 25, 2024 406,809 $38.04 to $39.4432 $38.585 July 26, 2024 103,926 $38.12 to $39
  • $38.12 — 4432 $38.585 July 26, 2024 103,926 $38.12 to $39.77 $39.05 July 29, 2024 158,
  • $39.77 — 585 July 26, 2024 103,926 $38.12 to $39.77 $39.05 July 29, 2024 158,090 $38.0
  • $39.05 — ly 26, 2024 103,926 $38.12 to $39.77 $39.05 July 29, 2024 158,090 $38.095 to $3
  • $38.095 — 39.77 $39.05 July 29, 2024 158,090 $38.095 to $39.08 $38.8528 (d) None. (e)
  • $39.08 — 05 July 29, 2024 158,090 $38.095 to $39.08 $38.8528 (d) None. (e) Not applic
  • $38.8528 — y 29, 2024 158,090 $38.095 to $39.08 $38.8528 (d) None. (e) Not applicable. CU

Filing Documents

SIGNATURES

SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date : July 30, 2024 The Carlyle Group Inc. By: /s/ Anne Frederick, attorney-in-fact Name: John C. Redett Title: Chief Financial Officer Carlyle Holdings II GP L.L.C. By: The Carlyle Group Inc., its sole member By: /s/ Anne Frederick, attorney-in-fact Name: John C. Redett Title: Chief Financial Officer Carlyle Holdings II L.L.C. By: /s/ Anne Frederick, attorney-in-fact Name: John C. Redett Title: Managing Director CG Subsidiary Holdings L.L.C. By: /s/ Anne Frederick, attorney-in-fact Name: John C. Redett Title: Managing Director TC Group Cayman Investment Holdings, L.P. By: CG Subsidiary Holdings L.L.C., its general partner By: /s/ Anne Frederick, attorney-in-fact Name: John C. Redett Title: Managing Director TC Group Cayman Investment Holdings Sub L.P. By: TC Group Cayman Investment Holdings, L.P., its general partner By: CG Subsidiary Holdings L.L.C., its general partner By: /s/ Anne Frederick, attorney-in-fact Name: John C. Redett Title: Managing Director TC Group VI Cayman, L.L.C. By: /s/ Jeremy W. Anderson Name: Jeremy W. Anderson Title: Vice President TC Group VI Cayman, L.P. By: TC Group VI Cayman, L.L.C., its general partner By: /s/ Jeremy W. Anderson Name: Jeremy W. Anderson Title: Vice President Carlyle Partners VI Cayman Holdings, L.P. By: TC Group VI Cayman, L.P., its general partner By: TC Group VI Cayman, L.L.C., its general partner By: /s/ Jeremy W. Anderson Name: Jeremy W. Anderson Title: Vice President

View Full Filing

View this SC 13D/A filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.